-
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
NASDAQ: $REGN TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (anti-GDF8/anti-myostatin) for its potential to prevent lean mass and… Source: Read More
-
Novo’s CagriSema Was Associated with 25% Weight Loss on Average for Women in a Post Hoc Analysis of REDEFINE 1
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Oct. 20, 2026 /PRNewswire/ — Today, Novo announced results from two post hoc analyses of the REDEFINE 1 trial presented at The Menopause Society 2026 Annual Meeting in San Diego. In an analysis of… Source: Read More
-
CagriSema vs. Tirzepatide: Insights from the REIMAGINE 5 Trial
A New Frontier in Weight Management The landscape of obesity treatment is evolving rapidly, and recent data from the REIMAGINE 5 trial has provided a compelling look at the next generation of weight-loss therapies. Novo Nordisk has shared results comparing their investigational drug, CagriSema, directly against tirzepatide (marketed as Zepbound/Mounjaro), marking a significant milestone in…
-
Boehringer Ingelheim’s Survodutide Achieves up to 13.1% Weight Loss in New Phase III Trial, Alongside Significant Improvements in Glycemic Control in People with Obesity and Type 2 Diabetes
Ingelheim, Germany, October 1, 2026 — Boehringer Ingelheim today announced positive results from the Phase III SYNCHRONIZE-2 trial, which investigates the glucagon/GLP-1 receptor dual agonist survodutide (BI 456906) in adults living with… Source: Read More